A5066203287- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Musculoskeletal pain and rehabilitation
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Treatment of Major Depression
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Mental Health Research Topics
- Botulinum Toxin and Related Neurological Disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Spine and Intervertebral Disc Pathology
- Pain Mechanisms and Treatments
- Lung Cancer Diagnosis and Treatment
- Inhalation and Respiratory Drug Delivery
- Multiple and Secondary Primary Cancers
- Gastrointestinal motility and disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Mental Health Treatment and Access
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Eating Disorders and Behaviors
- Pharmaceutical Economics and Policy
- Pain Management and Placebo Effect
Bristol-Myers Squibb (United States)
2018-2025
Technion – Israel Institute of Technology
2025
University of Wisconsin–Madison
2024
Hunan Cancer Hospital
2024
Johns Hopkins University
2024
Dana-Farber Cancer Institute
2024
Shanghai Chest Hospital
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
National Cancer Center
2024
Central South University
2024
We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status.Adults stage IV/recurrent cancer without EGFR mutations or ALK alterations and PD-L1 ≥ 1% < (n = 1739) were randomly assigned. Patients assigned to first-line ipilimumab, alone, chemotherapy. chemotherapy, End points included exploratory for...
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients resectable non-small-cell lung cancer (NSCLC). Perioperative (i.e., therapy followed by surgery and adjuvant therapy) may further improve clinical outcomes.
In CheckMate 227 (NCT02477826), patients with treatment-naive stage IV or recurrent NSCLC and 1% greater tumor programmed death ligand 1 expression had significantly improved overall survival nivolumab plus ipilimumab versus chemotherapy. We present the patient-reported outcomes (PROs).Patients (N = 1189) were randomized to ipilimumab, nivolumab, PROs exploratory. Changes in Lung Cancer Symptom Scale (LCSS) average symptom burden index, LCSS 3-item global EQ-5D visual analog scale (VAS),...
In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs).
Abstract Background In CheckMate 214 (median follow-up, 25.2 months), nivolumab plus ipilimumab yielded greater overall survival (OS) benefit than sunitinib in patients with intermediate-/poor-risk advanced renal cell carcinoma (aRCC). Health-related quality of life (HRQoL) assessed by the Functional Assessment Cancer Therapy-Kidney Symptom Index-19 (FKSI-19) was also more favorable for group group. We investigated whether HRQoL scores can predict OS 5 years follow-up 214. Patients and...
Background:Exacerbations are a major contributor to the large burden of treating chronic obstructive pulmonary disease (COPD). Estimates exacerbation costs in United States limited.Objective:To estimate incremental associated with COPD exacerbation, particularly severe States.Methods:COPD patients at least one were identified Thomson Reuters MarketScan administrative claims database. A was defined as patient use oral or parenteral corticosteroids on same day within 7 days following claim...
Background In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus (4 in patients metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years). Methods (N = 719) randomised 1:1 to or alone, disease-related symptom burden health-related quality of...
483 Background: SOR is approved as 1L therapy for pts with aHCC, but there still an unmet need to help improve or maintain HRQoL. This phase 3 study compared HRQoL of NIVO vs in aHCC exploratory endpoint. Methods: FACT-Hep was administered cycle 1, day 1 and every other cycle. The effect on using assessed via repeated measures mixed models (MMRM). Kaplan–Meier curves Cox proportional-hazards determined between-treatment differences time first until definitive deterioration (TTD/TUDD) based...
Open quantum systems that comply with the master equation and detailed balance decay in a non-oscillatory manner to thermal equilibrium. Beyond weak coupling limit, break microreversibility (e.g., presence of magnetic fields) violate but still thermalize. We study thermalization these show temperature increase produces novel exceptional points indicate sharp transition dynamics. A further fuels oscillations energy level populations, even without coherences. Moreover, violation introduces an...
Abstract Background Therapeutic advances in lung cancer have turned attention toward patient‐reported outcome measures (PROMs) as important clinical outcomes. The Functional Assessment of Cancer Therapy‐Lung (FACT‐L) is a common endpoint trials. This study calculated FACT‐L reference values for the United States (US) general population. Methods Adults from US population ( N = 2001) were surveyed between September 2020 and November 2020. Surveys contained 126 questions, including [36 items;...
Abstract Background Anemia is a frequent complication of chronic kidney disease (CKD) that negatively affects patients’ health-related quality life. Methods We conducted qualitative concept elicitation (CE) and cognitive debriefing (CD) interviews to assess the frequency, duration, severity symptoms impacts associated with anemia CKD facilitate development new patient-reported outcome (PRO) measure. interviewed 36 patients hemoglobin levels ≥8.0 <12.0 g/dL using semi-structured interview...
LBA9025 Background: In CheckMate 227 part 1 (NCT02477826), 1L NIVO + IPI demonstrated long-term, durable survival benefit vs platinum-doublet chemo in patients (pts) with metastatic NSCLC regardless of tumor programmed death ligand (PD-L1) expression level. Here we present the longest reported follow-up (5 y) a phase 3 trial combination immunotherapy NSCLC. Methods: Adults previously untreated stage IV or recurrent NSCLC, no known EGFR/ ALK alterations , and an ECOG performance status ≤ were...
Score reproducibility is an important measurement property of fit-for-purpose patient-reported outcome (PRO) measures. It commonly assessed via test-retest reliability, and best evaluated with a stable participant sample, which can be challenging to identify in diseases highly variable symptoms. To provide empirical evidence comparing the retrospective (patient global impression change [PGIC]) current state severity [PGIS]) approaches identifying subgroup for analyses, 3 PRO Consortium...
BackgroundThe comparative efficacy and health-related quality of life (HRQoL) outcomes nivolumab plus cabozantinib versus pembrolizumab axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not been assessed in head-to-head trials.ObjectiveTo assess the HRQoL axitinib.Design, setting, participantsPatient-level data from CheckMate 9ER trial published KEYNOTE-426 were used. reweighted to match key baseline characteristics reported KEYNOTE-426.InterventionNivolumab...
Background To reduce pharmacy costs, managed care organizations encourage therapeutic substitution from brand to a generic product. However, little is known about whether these cost-containment strategies can also potentially lower total expenditures for payers in treatment of major depressive disorder (MDD). Objective: compare economic outcomes patients with MDD who were switched selective serotonin reuptake inhibitor (SSRI) an alternative SSRI nonmedical reasons versus continued on the...
Abstract We describe the mixed-methods (qualitative and quantitative) development preliminary validation of Patient Assessment for Low Back Pain–Symptoms (PAL-S), a patient-reported outcome measure use in chronic low back pain (cLBP) clinical trials. Qualitative methods (concept elicitation cognitive interviews) were used to identify refine symptom concepts quantitative (classical test theory Rasch measurement theory) evaluate item- scale-level performance using an iterative approach....
Objectives:To use techniques of decision-analytic modeling to evaluate the effectiveness and costs linaclotide vs lubiprostone in treatment adult patients with irritable bowel syndrome constipation (IBS-C).Methods:Using model inputs derived from published literature, Phase III trial data a physician survey, decision-tree was constructed. Response therapy defined as (1) ≥14-point increase baseline IBS-Quality-of-Life (IBS-QoL) questionnaire overall score at week 12 or (2) one top two...